• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Keen Vision Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    3/28/25 4:00:33 PM ET
    $KVAC
    Get the next $KVAC alert in real time by email
    false 0001889983 00-0000000 0001889983 2025-03-24 2025-03-24 0001889983 KVAC:UnitsEachConsistingOfOneOrdinaryShareAndOneRedeemableWarrantToAcquireOneOrdinaryShareMember 2025-03-24 2025-03-24 0001889983 KVAC:OrdinaryShares0.0001ParValueMember 2025-03-24 2025-03-24 0001889983 KVAC:WarrantsEachExercisableForOneOrdinaryShareAtExercisePriceOf11.50Member 2025-03-24 2025-03-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    United States

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    March 24, 2025

    Date of Report (Date of earliest event reported)

     

    KEEN VISION ACQUISITION CORPORATION

    (Exact Name of Registrant as Specified in its Charter)

     

    British Virgin Islands   001-41753   n/a
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    37 Greenbriar Drive

    Summit, New Jersey

      07901
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (203) 609-1394

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

     

    Securities registered pursuant to Section 12(b) of the Act: None.

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one ordinary share and one redeemable warrant to acquire one ordinary share   KVACU   The Nasdaq Stock Market LLC
    Ordinary Shares, $0.0001 par value   KVAC   The Nasdaq Stock Market LLC
    Warrants, each exercisable for one ordinary share at an exercise price of $11.50   KVACW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    The disclosure contained in Item 2.03 is incorporated by reference in this Item 1.01

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    On March 24, 2025, Keen Vision Acquisition Corporation (the “Company”) issued an unsecured promissory note in the aggregate principal amount of $200,000 (the “Note”) to KVC Sponsor LLC, the Company’s initial public offering sponsor (“Sponsor”) in exchange for Sponsor depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination. The Note does not bear interest and matures upon the closing of a business combination by the Company. In addition, the Note may be converted by the holder into units of the Company identical to the units issued in the Company’s initial public offering at a price of $10.00 per unit.

     

    Item 8.01 Other Events

     

    The Company extended the business combination period to April 27, 2025, by depositing $200,000 to the trust account on March 24, 2025.

     

    Item 9.01. Financial Statements and Exhibits.

     

    Exhibit No.   Description
    10.1   Promissory Note dated March 24, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: March 28, 2025 Keen Vision Acquisition Corporation
         
      By: /s/ WONG, Kenneth Ka Chun
      Name:  WONG, Kenneth Ka Chun
      Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $KVAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KVAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KVAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

      BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy treatment delivered through a proprietary minimally invasive intracoronary infusion methodology, were presented at the 2025 HFpEF Summit held March 19-21, 2025, in Beverly Hills, CA. Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year. Heart failure with preserved ejection fraction (HFp

      4/1/25 8:00:00 AM ET
      $KVAC
    • Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

      BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-generation therapeutics, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed its planned review of the MUSIC-HFrEF Phase 1b/2 clinical trial data, recommending the completion of the Phase 1b portion and clearance to initiate the Phase 2 portion of the trial evaluating the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HFrEF). HFrEF is a prevalent form of heart disease that accounts for half of an estimated 64.3

      3/20/25 8:00:00 AM ET
      $KVAC
    • Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

      BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics, today announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HErEF). HErEF is a prevalent form of heart disease that accounts for half of an estimated 64.3 million heart failure cases worldwide and is currently considered a mass market incurable disease. The MUSIC-HFrEF trial is an open-label, uncontrolled st

      3/11/25 9:09:44 AM ET
      $KVAC

    $KVAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Keen Vision Acquisition Corporation

      SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

      11/14/24 9:07:56 PM ET
      $KVAC
    • SEC Form SC 13G filed by Keen Vision Acquisition Corporation

      SC 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

      11/14/24 6:03:06 PM ET
      $KVAC
    • Amendment: SEC Form SC 13G/A filed by Keen Vision Acquisition Corporation

      SC 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

      11/12/24 4:07:50 PM ET
      $KVAC

    $KVAC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Keen Vision Acquisition Corporation

      10-Q - Keen Vision Acquisition Corp. (0001889983) (Filer)

      5/14/25 4:00:41 PM ET
      $KVAC
    • Amendment: SEC Form SCHEDULE 13G/A filed by Keen Vision Acquisition Corporation

      SCHEDULE 13G/A - Keen Vision Acquisition Corp. (0001889983) (Subject)

      5/13/25 6:36:16 AM ET
      $KVAC
    • SEC Form SCHEDULE 13G filed by Keen Vision Acquisition Corporation

      SCHEDULE 13G - Keen Vision Acquisition Corp. (0001889983) (Subject)

      5/1/25 4:43:49 PM ET
      $KVAC